Malignant Pleural Effusion and Ascites Induce Epithelial-Mesenchymal Transition and Cancer Stem-Like Cell Properties Via the Vascular Endothelial Growth Factor (vegf)/phosphatidylinositol 3-Kinase (pi3k)/akt/mechanistic Target of Rapamycin (mtor) Pathway

Tao Yin,Guoping Wang,Sisi He,Guobo Shen,Chao Su,Yan Zhang,Xiawei Wei,Tinghong Ye,Ling Li,Shengyong Yang,Dan Li,Fuchun Guo,Zeming Mo,Yang Wan,Ping Ai,Xiaojuan Zhou,Yantong Liu,Yongsheng Wang,Yuquan Wei
DOI: https://doi.org/10.1074/jbc.m116.753236
2016-01-01
Abstract:Malignant pleural effusion (PE) and ascites, common clinical manifestations in advanced cancer patients, are associated with a poor prognosis. However, the biological characteristics of malignant PE and ascites are not clarified. Here we report that malignant PE and ascites can induce a frequent epithelial-mesenchymal transition program and endow tumor cells with stem cell properties with high efficiency, which promotes tumor growth, chemoresistance, and immune evasion. We determine that this epithelial-mesenchymal transition process is mainly dependent on VEGF, one initiator of the PI3K/Akt/mechanistic target of rapamycin (mTOR) pathway. From the clinical observation, we define a therapeutic option with VEGF antibody for malignant PE and ascites. Taken together, our findings clarify a novel biological characteristic of malignant PE and ascites in cancer progression and provide a promising and available strategy for cancer patients with recurrent/refractory malignant PE and ascites.
What problem does this paper attempt to address?